Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Analyst picks & changes

Amgen Inc.

(AMGN)

Oppenheimer & Co. analyst Matthew Geller raised Amgen Inc. to a "buy" from "market performer," prior to Friday's announcement of the deal with Synergen Inc. He said that if

Read the full 327 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE